Breaking News

Huons Acquires Stake in PanGen to Bolster Biopharma Business

Plans to secure management rights and incorporate PanGen as a subsidiary.

Author Image

By: Charlie Sternberg

Associate Editor

Huons Co. Ltd. has announced a strategic investment of KRW 14.3 billion ($10.4 million) in PanGen Biotech Inc. to strengthen its biopharmaceutical R&D and CDMO capabilities.   The investment will see Huons acquire 2,647,378 shares of PanGen, giving it a 31.53% stake in the company. Following the acquisition, Huons plans to secure management rights and incorporate PanGen as a subsidiary.   PanGen brings to the table GMP facilities for biopharmaceutical production, as well as a proprietary...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters